FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
PHARMACOPEIA INC [ PCOP ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 12/23/2008 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 12/23/2008 | D | 39,813.77 | D | (1) | 0 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Incentive Stock Option (right to buy) | $3.84 | 12/23/2008 | D | 24,182 | 02/25/2009(2) | 02/25/2018 | Common Stock | 24,182 | $0.2 | 0 | D | ||||
Incentive Stock Option (right to buy) | $4.3182 | 12/23/2008 | D | 7,700 | 10/17/2003(2) | 10/17/2012 | Common Stock | 7,700 | $0.2 | 0 | D | ||||
Incentive Stock Option (right to buy) | $4.67 | 12/23/2008 | D | 10,212 | 02/28/2008(2) | 02/28/2017 | Common Stock | 10,212 | $0.2 | 0 | D | ||||
Incentive Stock Option (right to buy) | $4.75 | 12/23/2008 | D | 24,831 | (2) | 03/01/2016 | Common Stock | 24,831 | $0.2 | 0 | D | ||||
Incentive Stock Option (right to buy) | $4.9432 | 12/23/2008 | D | 14,027 | 06/21/2000(2) | 06/21/2009 | Common Stock | 14,027 | $0.2 | 0 | D | ||||
Incentive Stock Option (right to buy) | $6.2 | 12/23/2008 | D | 28,524 | (2) | 05/04/2016 | Common Stock | 28,524 | $0.2 | 0 | D | ||||
Incentive Stock Option (right to buy) | $8.8818 | 12/23/2008 | D | 22,000 | 03/16/2005(2) | 03/16/2014 | Common Stock | 22,000 | $0.2 | 0 | D | ||||
Incentive Stock Option (right to buy) | $19.7727 | 12/23/2008 | D | 10,925 | 07/11/2001(2) | 07/11/2010 | Common Stock | 10,925 | $0.2 | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $3.84 | 12/23/2008 | D | 55,818 | 02/25/2009(2) | 02/25/2018 | Common Stock | 55,818 | $0.2 | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $4.67 | 12/23/2008 | D | 24,788 | 02/28/2008(2) | 02/28/2017 | Common Stock | 24,788 | $0.2 | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $4.75 | 12/23/2008 | D | 338 | 10/17/2003(2) | 03/01/2016 | Common Stock | 338 | $0.2 | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $5.3045 | 12/23/2008 | D | 12,760 | 09/24/2002(2) | 09/24/2011 | Common Stock | 12,760 | $0.2 | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $6.2 | 12/23/2008 | D | 46,478 | (2) | 05/04/2016 | Common Stock | 46,478 | $0.2 | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $19.7727 | 12/23/2008 | D | 74 | 07/11/2001(2) | 07/11/2010 | Common Stock | 74 | $0.2 | 0 | D |
Explanation of Responses: |
1. Disposed of pursuant to merger agreement between Pharmacopeia, Inc. ("Pharmacopeia"), Ligand Pharmaceuticals Incorporated ("Ligand") , Margaux Acquisition Corp., a wholly-owned subsidiary of Ligand, and Latour Acquisition, LLC, a wholly-owned subsidiary of Ligand, in exchange for approximately 23,828.54 shares of Ligand common stock having a market value of $2.58 per share on the effective date of the merger and $12,342.27 in cash, without interest. In addition, the reporting person received one contingent value right ("CVR") for each share of the Pharmacopeia common stock disposed of in the merger by the reporting person. The CVRs provide each holder the right to receive approximately $0.50 per share if Ligand enters into a license, sale, development, marketing or option agreement with respect to certain product candidates (other than any agreement with Bristol-Myers Squibb Company or any of its affiliates) on or prior to December 31, 2011. |
2. This option was canceled in connection with Pharmacopeia's offer to purchase all outstanding options, whether vested or unvested, to purchase shares of Pharmacopeia common stock, par value $0.01 per share, which was consummated on December 23, 2008. The reporting person received a cash payment of $0.20 per share of common stock issuable upon exercise of each such option. |
By: Justin Vogel For: Brian Posner | 12/24/2008 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |